Novo Nordisk

Novo Nordisk recruits new staff, lays off others as US R&D consolidated in Boston
Fierce Biotech
Thu, 03/2/23 - 10:37 am
Novo Nordisk
layoffs
hirings
R&D
Boston
Big-sellers from Merck, Novo and Lilly likely to face Medicare price negotiations: report
Fierce Pharma
Tue, 02/28/23 - 10:39 pm
Medicare
drug pricing
Merck
Novo Nordisk
Eli Lilly
Boehringer Ingelheim
JNJ
Novo sows the seeds for a new heart failure approach
EP Vantage
Wed, 02/22/23 - 09:50 am
Novo Nordisk
HS-001
cell therapy
heart failure
Novo Nordisk apologizes for not disclosing sponsorship of anti-obesity training
Financial Times
Mon, 02/13/23 - 10:44 am
Novo Nordisk
obesity
UK
Saxenda
Heart hope for Heartseed/Novo Nordisk HS-001 cell therapy
Pharmaphorum
Fri, 02/10/23 - 10:21 am
Novo Nordisk
Heartseed
clinical trials
HS-001
cell therapy
heart failure
Novo Nordisk notches big GLP-1 sales amid rebounding supplies, but cautions on future 'periodic constraints'
Endpoints
Thu, 02/2/23 - 10:46 am
Novo Nordisk
Wegovy
earnings
AstraZeneca, Novo Nordisk and Sanofi score 340B-related appeals court win over HHS
Endpoints
Mon, 01/30/23 - 05:58 pm
AstraZeneca
Sanofi
Novo Nordisk
340B
drug discounts
Top 10 Pharma TV Ad Spenders in 2022 — Anti-Inflammatories and Diabetes Drugs Dominate
Xtalks
Sun, 01/29/23 - 01:31 pm
television ads
pharma marketing
DTC ads
AbbVie
Rinvoq
Dupixent
Sanofi
Regeneron
Skyrizi
Novo Nordisk
Ozempic
Jardiance
Eli Lilly
Boehringer Ingelheim
Rybelsus
Trulicity
Rexulti
Otsuka
Lundbeck
Tremfya
JNJ
Verzenio
Big caps bounce back for biopharma
EP Vantage
Mon, 01/16/23 - 11:14 am
pharma stocks
Amgen
BeiGene
Bristol Myers Squibb
Gilead Sciences
Lantheus Holdings
Madrigal Pharmaceuticals
Merck
Moderna Therapeutics
Novo Nordisk
Prometheus Biosciences
Roche
Novo Nordisk's GLP-1 for Type II diabetes approved for first-line treatment
Endpoints
Fri, 01/13/23 - 11:10 am
Novo Nordisk
Rybelsus
semaglutide
FDA
type 2 diabetes
diabetes
Novo Nordisk, AstraZeneca and Lilly will top pharma's revenue growth in 2023: report
Fierce Pharma
Sun, 01/8/23 - 09:57 pm
Pfizer
Merck
JNJ
Novo Nordisk
AstraZeneca
Novo Nordisk to go slow on Wegovy marketing after getting supply issues in check
Medical Marketing and Media
Thu, 01/5/23 - 04:54 pm
Novo Nordisk
obesity
Wegovy
pharma marketing
Big pharma’s new year catalysts
EP Vantage
Mon, 12/19/22 - 11:05 am
AstraZeneca
Daiichi Sankyo
Pfizer
Roche
CSL
uniQure
Novo Nordisk
Eli Lilly
Despite flu admissions rising, Tamiflu fill rates are on the decline
Beckers Hospital Review
Thu, 12/15/22 - 11:18 pm
Flu
Tamiflu
Novo Nordisk
Novo Nordisk comments on role of off-label use in Ozempic shortfall
Medical Marketing and Media
Thu, 12/15/22 - 10:56 am
Novo Nordisk
Ozempic
diabetes
off label
drug shortages
‘Diabesity’ marketing set to swell as Novo preps relaunch of weight-loss drug
Medical Marketing and Media
Wed, 12/14/22 - 10:36 am
Novo Nordisk
pharma marketing
Wegovy
obesity
diabetes
NASH: Wall Street’s Forgotten Mega Blockbuster Indication
BioSpace
Mon, 12/12/22 - 10:13 am
NASH
Intercept Pharma
Novo Nordisk
Madrigal Pharmaceuticals
Inventiva
Galmed Pharmaceuticals
Amgen to push latecomer obesity drug into midstage testing
Pharmaphorum
Sun, 12/4/22 - 01:26 pm
Amgen
Novo Nordisk
Eli Lilly
obesity
clinical trials
AMG 133
Novo Nordisk invests $74M to boost API manufacturing for clinical trials
Fierce Biotech
Tue, 11/22/22 - 10:52 am
Novo Nordisk
clinical trials
APIs
API manufacturing
R&D
Looming obesity drug rivalry not a concern for Novo CEO
Reuters
Wed, 11/16/22 - 10:42 am
Novo Nordisk
Wegovy
obesity

Pages